GRAIL Announces FDA Advisory Committee Review Of Galleri Multi-Cancer Early Detection Test

GRAIL, Inc. (GRAL) announced that the U.S. FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet on September 23, 2026 to review the company's Premarket Approval application for Galleri, its multi-cancer early detection (MCED) blood test.